6月5日，科伦博泰生物盘中上涨3.54%，报405.8港元，成交额2817.64万港元。
消息面上，公司于6月4日发布公告，拟提请股东大会审议授权董事会回购不超过已发行H股总数10%的股份，释放积极信号。此外，公司核心产品芦康沙妥珠单抗III期研究成果近期于ASCO大会口头报告并同步发表于《柳叶刀》，数据显示在PD-L1阳性非小细胞肺癌中PFS风险比达0.35，系全球首个在该适应症中显示PFS改善的ADC药物。此前该股因业绩亏损扩大及董事长减持一度承压，回购方案叠加重磅临床数据有助修复市场情绪。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.